유전자 치료 시장 예측(-2030년) : 부문별, 지역별 세계 분석

According to Stratistics MRC, the Global Gene Therapy Market is accounted for $8.80 billion in 2023 and is expected to reach $32.66 billion by 2030 growing at a CAGR of 20.6% during the forecast period. Human gene therapy is a procedure that alters a person's genes to treat or cure disease. It aims to change or regulate a gene's expression or the biological characteristics of live cells for therapeutic purpose. Inactivating a disease-causing gene that is not working correctly, replacing a disease-causing gene with a healthy copy of the gene, and introducing a new or modified gene into the body to cure a disease are some of the ways that gene therapies can operate. Products utilizing gene therapy are being investigated for the treatment of diseases including cancer, genetic disorders, and infectious diseases.

According to the ACS 'Cancer Facts & Figures 2022', around 1,918,030 new cancer cases and 609,360 deaths due to cancers are estimated to be reported in the United States in 2022. In the treatment of cancer, various gene therapy strategies are currently employed.

Market Dynamics:

Driver:

Novel gene therapy techniques

Ailments that previously only received temporary therapies now have permanent remedies because to gene therapy. Gene therapy failed for a very long time; nevertheless, in recent years, successful and long-lasting treated instances have been documented. Promising results have been reached for a wide range of genetic ailments, including blood abnormalities, immunological inadequacies, eyesight problems, nerve cell regeneration, metabolic disorders, and several cancer kinds. Gene therapy has the potential to be a personalized treatment that can "cure" a range of diseases with more specificity and fewer negative effects. Gene therapy is the practice of transferring genetic material to a patient in order to treat a disease or, at the very least, improve their clinical state which enhances the growth of the market.

Restraint:

Gene therapy products are subject to strict restrictions

Globally, the use of gene therapy is expanding quickly because to the aging population and a number of chronic diseases that can be avoided with early detection and prompt treatment. Likewise, in order to receive clearance from higher authorities for the product's introduction in an area, gene therapy market participants must go by a set of rules. One of the most challenging duties among all the procedures is adhering to these strict restrictions. Different gene therapy medicines have different pre-market approval levels depending on the nation.

Opportunity:

Increasing rates of neurological and oncological disorders

Rare genetic illnesses are becoming more common among people all over the world. The National Organization for Rare Diseases (NORD) estimates that 1 in 10,000 live births in the United States occur each year due to spinal muscular atrophy. The profession has experienced technological developments that have made it easier to cure diseases that were formerly thought to be incurable. On the other hand, one of the most common diseases in the world is cancer. These gene treatments assist individuals who are especially susceptible to developing specific forms of cancer due to genetic mutations handed down from the previous generation in preventing the disease.

Threat:

High cost of treatment

In order to treat an illness, a patient's genome may be altered, deleted, or added to as part of a novel medical procedure known as gene therapy. Gene therapy has already demonstrated significant promise for the treatment and even cure of once-intractable disorders, despite the fact that it is still in its infancy. In many countries, the cost of gene therapy is still largely unregulated and decided on a case-by-case basis, typically focused on a single upfront payment.

COVID-19 Impact:

Due to a decrease in the number of cancer patients visiting hospitals and clinics for gene therapy (ICI), which resulted in a decrease in demand for gene therapy products, COVID-19's overall impact on the market for gene therapy remained unfavorable. For instance, the NCBI estimates that the number of cancer patients in the U.S. would drop by around 50% by 2020, and that the market's demand for gene therapy products will also drop by about 50% during COVID-19.

The viral vectors segment is expected to be the largest during the forecast period

The viral vectors segment is estimated to have a lucrative growth, due to the ability to control viral vectors to express therapeutic genes makes them the most efficient method of gene transfer for altering a particular cell type or tissue. Several virus types are being researched right now for their potential to be used to transfer genes to cells for either temporary or permanent transgenic expression. In order to circumvent immune monitoring by an infected host, viruses have evolved to become extremely effective at delivering nucleic acids to a limited range of cell types. These characteristics make viruses appealing gene delivery vectors for gene therapy, thus propelling the growth of the market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, as the prevalence is caused by the treatment modalities' great availability and accessibility in such institutions. Throughout the projection period, it is expected that this market segment will continue to rule. Due to the rise of independent clinics offering cutting-edge treatments for neurological and cancer disorders, the clinics market is also expected to expand.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the number of approvals and the amount of money made throughout the projected period, and the market will continue to grow as more major and small businesses make R&D expenditures in the creation of medications for optimum therapy. The market is also being driven by the governments' expanding investment levels and the rising incidence of certain ailments. The Spinal Muscular Atrophy Foundation estimates that between 10,000 and 25,000 children and adults in the United States will have spinal muscular atrophy by the year 2020, making it a reasonably prevalent condition.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the country's sizable population's unmet medical demands and rising need for breakthrough technology in the management of uncommon but steadily escalating diseases. Due to the easy access to resources, the presence of big corporations locally, and rising government funding, the Asia Pacific market for the commercial use of genetic treatments is predicted to have considerable expansion over the projected period.

Key players in the market:

Some of the key players profiled in the Gene Therapy Market include: Amgen Inc. , Biogen Inc., Bluebird Bio Inc., Gilead Sciences Inc., Novartis AG, F. Hoffmann-La Roche Ltd, UniQure NV, Abeona Therapeutics Inc., Generation Bio, Poseida Therapeutics, Astellas Pharma, Voyager Therapeutics Inc., Jazz Pharmaceuticals, Inc, GlaxoSmithKline plc, Spark Therapeutics Inc, Sarepta Therapeutics, Orchard Therapeutics, Shenzhen SiBiono GeneTech, Shanghai Sunway Biotech Co. Ltd. and CRISPR Therapeutics AG

Key Developments:

In August 2023, Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years. The results were presented in a late-breaking session at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam.

In July 2023, Biogen to Acquire Reata Pharmaceuticals, Reata has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases.

In February 2023, Kite, a Gilead Company announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

Vectors Covered:

• Non-Viral Vectors
• Viral Vectors

Gene Types Covered:

• Antigen
• Cytokine
• Tumor Suppressor
• Suicide
• Deficiency
• Growth factors
• Receptors
• Other Gene Types

Delivery Methods Covered:

• In Vivo
• Ex Vivo

Applications Covered:

• DMD (Duchenne Muscular Dystrophy)
• Neurological Diseases
• Cancer
• Hepatological Diseases
• Rare Diseases
• Oncological Disorders
• Acute Lymphoblastic Leukemia (ALL)
• Peripheral arterial disease
• Other Applications

End Users Covered:

• Cancer Institutes
• Hospitals
• Research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Gene Therapy Market, By Vector

• 5.1 Introduction
• 5.2 Non-Viral Vectors
  • 5.2.1 Oligonucleotides
  • 5.2.2 Other Non-Viral Vectors
• 5.3 Viral Vectors
  • 5.3.1 Retro Viral Vectors
  • 5.3.2 Adeno-Associated Virus Vectors
  • 5.3.3 Lentiviral Vector
  • 5.3.4 Herpes Virus Vector
  • 5.3.5 Other Viral Vectors

6 Global Gene Therapy Market, By Gene Type

• 6.1 Introduction
• 6.2 Antigen
• 6.3 Cytokine
• 6.4 Tumor Suppressor
• 6.5 Suicide
• 6.6 Deficiency
• 6.7 Growth factors
• 6.8 Receptors
• 6.9 Other Gene Types

7 Global Gene Therapy Market, By Delivery Method

• 7.1 Introduction
• 7.2 In Vivo
• 7.3 Ex Vivo

8 Global Gene Therapy Market, By Application

• 8.1 Introduction
• 8.2 DMD (Duchenne Muscular Dystrophy)
• 8.3 Neurological Diseases
• 8.4 Cancer
• 8.5 Hepatological Diseases
• 8.6 Rare Diseases
• 8.7 Oncological Disorders
• 8.8 Acute Lymphoblastic Leukemia (ALL)
• 8.9 Peripheral arterial disease
• 8.10 Other Applications

9 Global Gene Therapy Market, By End User

• 9.1 Introduction
• 9.2 Cancer Institutes
• 9.3 Hospitals
• 9.4 Research Institutes
• 9.5 Other End Users

10 Global Gene Therapy Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Amgen Inc.
• 12.2 Biogen Inc.
• 12.3 Bluebird Bio Inc.
• 12.4 Gilead Sciences Inc.
• 12.5 Novartis AG
• 12.6 F. Hoffmann-La Roche Ltd
• 12.7 UniQure NV
• 12.8 Abeona Therapeutics Inc.
• 12.9 Generation Bio
• 12.10 Poseida Therapeutics
• 12.11 Astellas Pharma
• 12.12 Voyager Therapeutics Inc.
• 12.12 Jazz Pharmaceuticals, Inc
• 12.14 GlaxoSmithKline plc
• 12.15 Spark Therapeutics Inc
• 12.16 Sarepta Therapeutics
• 12.17 Orchard Therapeutics
• 12.18 Shenzhen SiBiono GeneTech
• 12.19 Shanghai Sunway Biotech Co. Ltd.
• 12.20 CRISPR Therapeutics AG